INSP

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.

Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.

Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.

ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.

Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.

Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.

Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems NYSE: INSP reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting it to raise its full-year outlook for revenue, adjusted operating margin and adjusted earnings per share.